Literature DB >> 10650183

A potent and highly selective nonpeptidyl nociceptin/orphanin FQ receptor (ORL1) antagonist: J-113397.

S Ozaki1, H Kawamoto, Y Itoh, M Miyaji, Y Iwasawa, H Ohta.   

Abstract

We discovered a potent nociceptin/orphanin FQ receptor (ORL1) receptor antagonist, J-113397 (1-[(3R, 4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one). J-113397 inhibited [125I][Tyr(14)]nociceptin binding to Chinese hamster ovary (CHO) cells expressing ORL1 receptor in a dose-dependent manner (IC(50); 2. 3 nM), but showed 600-fold or less affinity for mu-, delta- and kappa-opioid receptors. Nociceptin/orphanin FQ-induced suppression of cyclic AMP accumulation elicited by forskolin was completely inhibited by J-113397 with an IC(50) value of 26 nM. These results indicate that J-113397 is a potent and selective nonpeptidyl antagonist of the ORL1 receptor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10650183     DOI: 10.1016/s0014-2999(99)00822-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  16 in total

1.  Enhanced spinal nociceptin receptor expression develops morphine tolerance and dependence.

Authors:  H Ueda; M Inoue; H Takeshima; Y Iwasawa
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  A new synthesis of the ORL-1 antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397) and activity in a calcium mobilization assay.

Authors:  Emilie D Smith; N Ariane Vinson; Desong Zhong; Bertold D Berrang; Jennifer L Catanzaro; James B Thomas; Hernán A Navarro; Brian P Gilmour; Jeffrey Deschamps; F Ivy Carroll
Journal:  Bioorg Med Chem       Date:  2007-10-13       Impact factor: 3.641

Review 3.  Managing Parkinson's disease: moving ON with NOP.

Authors:  Daniela Mercatelli; Erwan Bezard; Roberto Eleopra; Nurulain T Zaveri; Michele Morari
Journal:  Br J Pharmacol       Date:  2020-01-03       Impact factor: 8.739

4.  Pharmacological properties of nociceptin/orphanin FQ-induced stimulation and inhibition of cyclic AMP formation in distinct layers of rat olfactory bulb.

Authors:  Maria C Olianas; Pierluigi Onali
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 5.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

6.  Involvement of the N/OFQ-NOP system in rat morphine antinociceptive tolerance: Are astrocytes the crossroad?

Authors:  Laura Micheli; Elena Lucarini; Francesca Corti; Roberto Ciccocioppo; Girolamo Calò; Anna Rizzi; Carla Ghelardini; Lorenzo Di Cesare Mannelli
Journal:  Eur J Pharmacol       Date:  2018-01-31       Impact factor: 4.432

7.  G protein activation and cyclic AMP modulation by naloxone benzoylhydrazone in distinct layers of rat olfactory bulb.

Authors:  Pierluigi Onali; Maria C Olianas
Journal:  Br J Pharmacol       Date:  2004-09-27       Impact factor: 8.739

8.  Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone-inducible mammalian expression system.

Authors:  J McDonald; T A Barnes; H Okawa; J Williams; G Calo'; D J Rowbotham; D G Lambert
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

9.  Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior.

Authors:  Matteo Marti; Flora Mela; Carlo Veronesi; Remo Guerrini; Severo Salvadori; Mauro Federici; Nicola B Mercuri; Anna Rizzi; Gianfranco Franchi; Lorenzo Beani; Clementina Bianchi; Michele Morari
Journal:  J Neurosci       Date:  2004-07-28       Impact factor: 6.167

10.  The NOP (ORL1) receptor antagonist Compound B stimulates mesolimbic dopamine release and is rewarding in mice by a non-NOP-receptor-mediated mechanism.

Authors:  Miwako Koizumi; Kazuto Sakoori; Naoko Midorikawa; Niall P Murphy
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.